2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.32 Sun

PP01.32 Sun - Abstract

Pdf Summary

The study examined the impact of de novo co-mutations on clinical outcomes in patients with EGFR-mutated non-small cell lung cancer receiving first-line osimertinib. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor used as a first-line treatment for this type of lung cancer. The research aimed to understand how additional gene alterations affect response to osimertinib and subsequent clinical results. The study included patients with common EGFR mutations who underwent osimertinib monotherapy as their first-line treatment. Various gene alterations, including TP53, KRAS, and PIK3CA, were analyzed, with a focus on how these mutations affected treatment failure and overall survival. Patients with fewer co-mutations had longer overall survival than those with multiple mutations. Notably, alterations in genes related to epigenetic modification were associated with shorter overall survival. The study suggests that besides the primary driver mutation, the presence of secondary mutations, especially in genes related to epigenetic regulation, may impact treatment outcomes. Further research is needed to understand how tumor genomic complexity at the outset may influence patient outcomes. The findings highlight the importance of considering additional mutations beyond the primary driver mutation in the management of EGFR-mutated non-small cell lung cancer.

Keywords

de novo co-mutations

clinical outcomes

EGFR-mutated non-small cell lung cancer

osimertinib

gene alterations

response to treatment

TP53

KRAS

PIK3CA

tumor genomic complexity